Seventy patients with advanced head and neck cancer were treated with vinorelbine and continuous 5-FU administered in a central venous catheter. Over all response was 36% with 9% complete responses. The most common grade 3 and 4 toxicities were stomatitis (13), infection (5), pain related to vinorelbine infusion (4), skin toxicity (3). Thirty one patients had grade 3 or 4 leukopenia. Treatment was complicated by venous thrombosis in the central venous catheter in one case. A majority of patients experienced dose reduction of one or both drugs or treatment delays due to toxicity. Median time to progression was 4.7 months and overall median survival 6.6 months. We conclude that the regimen is feasible and tolerated with moderate toxicity. Response rates and time to progression are comparable to other studies with multi agent treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/02841860600959981 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Has PD-1 blockade changed the standard of care for cHL?
Hematology Am Soc Hematol Educ Program
December 2024
University of Washington, Fred Hutchinson Cancer Center, Seattle, WA.
The treatment paradigm for classic Hodgkin lymphoma (CHL) continues to evolve, particularly in light of the incorporation of programmed cell death protein 1 (PD-1) inhibitors into a variety of therapeutic settings. PD-1 inhibitors have demonstrated high efficacy and a favorable toxicity profile when added to a doxorubicin, vinblastine, dacarbazine chemotherapy backbone in patients with untreated CHL. PD-1 inhibitors are also effective treatment options in the relapsed/refractory setting.
View Article and Find Full Text PDFPeptide-Conjugated Vascular Endothelial Extracellular Vesicles Encapsulating Vinorelbine for Lung Cancer Targeted Therapeutics.
Nanomaterials (Basel)
October 2024
School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, China.
Article Synopsis
- Lung cancer treatment faces challenges due to non-specificity and damage to healthy cells, but nanoparticle-based drug delivery systems (NDDSs) offer potential solutions.
- Extracellular vesicles (EVs), particularly those isolated from human umbilical endothelial cells (HUVECs), can evade immune responses and deliver drugs with minimal toxicity.
- In this study, engineered GE11-HUVEC-EVs were loaded with the drug vinorelbine and demonstrated effective tumoricidal effects in lung cancer models, targeting cells that overexpress the epidermal growth factor receptor (EGFR).
Efficacy and safety of metronomic oral vinorelbine and its combination therapy as second- and later-line regimens for advanced non-small-cell lung cancer: a retrospective analysis.
Clin Transl Oncol
December 2024
Fujian Cancer Hospital, Clinical Oncology School of Fujian Medical University, Fuma Street, Jinan District, Fuzhou, 350014, China.
Objective: This retrospective analysis aimed to evaluate the efficacy and adverse reactions of metronomic oral vinorelbine and its combination therapy as second- and later-line regimens for advanced non-small-cell lung cancer (NSCLC).
Methods: NSCLC patients undergoing metronomic oral vinorelbine as second- and later-line regimens in Fujian Cancer Hospital from October 2018 to October 2022 were enrolled, and patients' demographic and clinical characteristics were collected. The efficacy and safety of metronomic oral vinorelbine monotherapy and its combination therapy regimens were compared.
Vinorelbine administration impedes the timely progression of meiotic maturation and induces aneuploidy in mouse oocytes.
Reprod Toxicol
September 2024
Department of Reproductive Medicine, Peking University Shenzhen Hospital, Shenzhen, China. Electronic address:
Vinorelbine is a commonly used drug to treat various malignancies, such as breast cancer, non-small cell lung cancer, and metastatic pleural mesothelioma. Its side effects include severe neutropenia, local phlebitis, gastrointestinal reactions, and neurotoxicity. In view of the scarcity of research on vinorelbine's reproductive toxicity, this study evaluated the impact of vinorelbine ditartrate, a commonly used form of vinorelbine, on oocyte maturation in vitro.
View Article and Find Full Text PDFAnthracycline-based hepatic arterial infusion chemotherapy achieved 17 months of disease regression in a patient with breast cancer liver metastases resistant to multiple systemic chemotherapies.
Int Cancer Conf J
April 2024
Department of Surgery, JCHO Yamatokoriyama Hospital, 1-62 Asahi-cho, Yamatokoriyama, Nara 6391013 Japan.
Hepatic arterial infusion chemotherapy (HAIC) for liver metastases (LMs) from breast cancer is not a standard of care, but its effectiveness in patients with extensive LMs who cannot tolerate systemic therapy has been reported. Herein, we report a case of breast cancer LMs that were controlled by anthracycline-based HAIC. A 46-year-old woman with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who had multiple LMs and bone metastases underwent seven lines of systemic therapy (paclitaxel/bevacizumab for 38 months; letrozole, nivolumab/fulvestrant, eribulin, gemcitabine/vinorelbine, high-dose toremifene/abemaciclib, and capecitabine for 21 months in total).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!